BioSpace News Archive

Today, the U.S. Food and Drug Administration authorized marketing of the GI Genius, the first device that uses artificial intelligence (AI) based on machine learning to assist clinicians in detecting lesions (such as polyps or suspected tumors) in the colon in real time during a colonoscopy

Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the presentation of data from the company’s HPK1 inhibitor program in a poster at the AACR Annual Meeting held virtually April 10-15, 2021.

Chemotherapy is a process that uses drugs for the control, cure, and palliation of cancer. Cancer, in its early stages, can be cured and controlled using chemotherapy.

Medication adherence is and umbrella term for systems used to upgrade adaptation to endorsed drugs.

Microbial identification has become an important aspect of the overall healthcare domain. With the growing prevalence of infectious diseases, increasing frequency of global pandemic, and rising food safety concerns the need for rapid and reliable microbial identification has become highly important.

The rising number of road accidents, coupled with the increasing popularity of medical tourism worldwide is a prime factor boosting the growth of the global ambulance services market during the forecast period, set between 2020 and 2030.

Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, announced that it has completed sales of approximately $47 million of American Depositary Shares pursuant to the Company’s ATM program established on March 29, 2021, through Jefferies LLC, acting as sales agent.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced the abstract results of the final 5 year immune response data of the Phase IIb clinical trial at the 2021 AACR Annual Meeting.

Amyris, Inc. announced the pricing of an underwritten public offering of an aggregate of 19,047,619 shares of its common stock at a public offering price of $15.75 per share, which consists of a secondary offering of 11,390,797 shares to be sold, in the aggregate, by DSM International B.V. and affiliates of Vivo Capital LLC and 7,656,822 shares to be sold by Amyris.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, confirmed it can successfully identify the “double mutant” variant of COVID-19 with its Lucira molecular test kit.